Sybron Quietly Builds a Powerhouse

Sybron International, hardly a well-known name in the diagnostics industry, has built a $350 million highly profitable diagnostics business by acquiring small, niche companies. Its latest acquisition, Microgenics Corp., makes it an important player in the drugs of abuse and therapeutic drug monitoring businesses. Microgenics had been part of Boehringer Mannheim Corp. But when Roche bought Boehringer Mannheim, the FTC required Roche to sell off Microgenics for anti-trust reasons. Microgenics was sold last summer to an investor group, which sold it to Sybron.

Hardly a well-known name, Sybron International Corp. , has quietly amassed a $350 million highly profitable diagnostics business over the years by acquiring well-run niche companies—and now considers itself the tenth largest company in the industry. Its latest acquisition, Microgenics Corp. [See Deal], strengthens its position in one of its core businesses—making reagents for drugs of abuse (DOA) testing and therapeutic drug monitoring (TDM).

Sybron is already a major OEM supplier of TDM and DOA reagents to Roche , Beckman Coulter Inc. ...

More from Archive

More from In Vivo